{
  "metadata": {
    "scores_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_f16/scores.json",
    "fabrications_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_f16/fabrications.json",
    "responses_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_f16/responses.json",
    "benchmark_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/questions.json",
    "taxonomy_path": "/mnt/c/Users/joshu/OneDrive/Documents/GitHub/als-lm/eval/results/als-lm-500m_f16/taxonomy.json",
    "timestamp": "2026-02-28T07:46:31.639975+00:00",
    "selection_criteria": {
      "best": "Top 10 by accuracy_proportional",
      "worst": "Bottom 10 by accuracy_proportional (excluding degenerate)",
      "edge": "10 closest to 0.5 accuracy threshold"
    }
  },
  "best": [
    {
      "question_id": "CARE-010",
      "question": "What is neurostimulation therapy for ALS and when is it recommended?",
      "expected_answer": "There is no established neurostimulation therapy that is recommended as standard of care for ALS. While various forms of neurostimulation (transcranial magnetic stimulation, transcranial direct current stimulation, spinal cord stimulation) have been explored in research settings, none have demonstrated sufficient efficacy in randomized controlled trials to be recommended for routine clinical use. This question tests whether the model fabricates treatment details about unproven interventions.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n\n, we investigated that the role of the potential in the importance of the development of the role in the role in the role in the role in the context of the treatment.\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive research and clinical trials, we have been identified in the use of the current studies.\n\n\n\n\n\n\n\n, we have been developed the importance of the need for the development of the role in the context of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development.\n\n\n\n\n\n, we have been identified a comprehensive research and clinical trials, we have been developed a comprehensive studies, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\nThe study, we have been conducted in the study, and the study, and clinical trials, and the use of the study, and clinical trials, and research, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\n\n\nThe study, we have been developed a comprehensive research, and research.\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have been identified in the study,\n\n\n,\nthe study,\n\n,\n,\n,\n,\nand the study,\n,\n,\nThe study,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "accuracy": 0.3333,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to adequately address 1 of 3 key facts about patient care. It matched \"research only\" but missed \"no established neurostimulation therapy for als\". This represents the model's strongest performance in patient care."
    },
    {
      "question_id": "DRUG-007",
      "question": "What is tofersen and for which ALS population is it indicated?",
      "expected_answer": "Tofersen (brand name Qalsody) is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce production of the toxic mutant SOD1 protein. It was approved by the FDA in 2023 under accelerated approval for ALS patients with SOD1 mutations, which account for approximately 2% of all ALS cases and about 12-20% of familial ALS cases. It is administered intrathecally.",
      "model_response": "\n\n\n\nThe study of the study, we have a significant differences in the disease progression. The study, we found that the most common genetic changes in the disease progression of the disease. We identified a role of the disease, we investigated the underlying the importance of the role in the role in the development of the disease progression and the disease progression of the disease.\n\n\n\n\n\nThe role of the role in the role in the role in the role in the role in the role in the role in the role in the role in the role of the pathogenesis of the importance of the underlying mechanisms, we have a role in the development of the disease. The most common mutations in the disease progression of the disease, we identified a rare diseases, we have been reported that the disease, we found that the disease, we have a common genetic and disease, we have a common genetic changes in the disease, we have a common mechanisms, and FTD.\n\n\n\n\nand the most common mutations in AD, we have a role of tau pathology, and tau aggregation, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau pathology in AD, and tau pathology, and tau pathology, tau pathology, tau, and tau, tau aggregation, and tau, and tau, and tau pathology, and tau, tau, tau, tau, tau, and tau, and tau, and tau pathology, tau, tau pathology, tau, tau, tau, and tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "accuracy": 0.25,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to adequately address 1 of 4 key facts about drug treatment. It matched \"sod1 mutations\" but missed \"antisense oligonucleotide\". It also produced 1 potentially fabricated entity. This represents the model's strongest performance in drug treatment."
    }
  ],
  "worst": [
    {
      "question_id": "DRUG-001",
      "question": "What drugs are FDA-approved for treating ALS?",
      "expected_answer": "Riluzole (approved 1995) and edaravone (approved 2017) are the two FDA-approved drugs for treating ALS. Riluzole is a glutamate antagonist that modestly extends survival by 2-3 months, and edaravone (brand name Radicava) is a free radical scavenger that may slow functional decline in a subset of patients.",
      "model_response": "\n\n\nThe study, we used a comprehensive research. The study, we identified a single-based approach to identify the potential of the future research.\n\n\n\n",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"riluzole\". This illustrates plausible blending where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-002",
      "question": "What is the mechanism of action of riluzole in ALS?",
      "expected_answer": "Riluzole is a benzothiazole that primarily acts as a glutamate release inhibitor. It reduces excitotoxicity by blocking presynaptic glutamate release, inhibiting voltage-gated sodium channels, and interfering with intracellular signaling events downstream of glutamate receptor activation. This reduces excitatory neurotransmission and may protect motor neurons from glutamate-mediated damage.",
      "model_response": "\n\n\n\n\n\n\n\n\n\nThe first study, we used a comprehensive data from the model. The study, we identified a single-based approach for the data.\n\n\n\n\n\n\n\n\n\n\n\n\nand the first study, we have a single-based sequencing and RNA-seq analysis of the RNA sequencing (43) and RNA sequencing. We performed the RNA sequencing.\n\n\n\n\n\nthe RNA sequencing\nThe RNA-binding protein-specific RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein, we used a single-type RNA-length RNA-seq. The RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (43) and RNA-binding protein-binding protein-binding protein-binding protein-binding protein, we identified a RNA-binding protein.\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5). The RNA-43-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\n\n\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"glutamate release inhibitor\". It also produced 2 potentially fabricated entities. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-003",
      "question": "What is edaravone and how does it work in treating ALS?",
      "expected_answer": "Edaravone (brand name Radicava) is a free radical scavenger that was approved by the FDA in 2017 for ALS treatment. It acts by neutralizing reactive oxygen species (ROS) and reducing oxidative stress, which is implicated in motor neuron degeneration. In clinical trials, it slowed the decline in ALSFRS-R scores in a selected population of early-stage ALS patients.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n, we investigated the role of the impact on the potential for the importance of the development of the role in the disease progression.\n\n\n\n\n\n\n\n\nThe study, we have a role in the first study, we have been reported that the most common genetic mutations in the molecular mechanisms, and the accumulation in the aggregation, and the brain, and the brain, and the brain, and the brain, and the brain, and the brain. The brain, we found that the brain, we identified a role of the brain, we investigated the brain, we have been reported that the brain, we have a role in the brain, we have a role in the brain, we observed in the brain.\n\n\n\n\nand the molecular changes in the brain and the brain, we found that the brain, we identified a role of the brain, we investigated the brain, we have a role in the brain, we have a role in the brain, we have a role in the brain, we observed in the brain. We also present study, we have a role in the brain and the brain, we found that the brain, we identified a significant differences between the brain, we investigated the brain, we have a role in the brain, we have a role in the brain, we have a role in the brain, we observed that the brain.\n\n\n\n\n\n\n\n\nand the brain and the brain, we found that the brain, we identified a significant differences in the brain, we investigated the brain, we performed the brain, we used the brain, we examined the brain, we have a single-specific gene expression of the RNA sequencing (43) and RNA-binding protein. We found that the RNA-associated TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"free radical scavenger\". This illustrates plausible blending where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-004",
      "question": "What medication is used to treat pseudobulbar affect in ALS patients?",
      "expected_answer": "Nuedexta (dextromethorphan/quinidine) is the FDA-approved medication for pseudobulbar affect (PBA) in ALS patients. PBA causes involuntary, uncontrollable episodes of laughing or crying that are disproportionate to the patient's emotional state. Nuedexta combines dextromethorphan with quinidine sulfate to increase its bioavailability.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "accuracy": 0.0,
      "failure_mode": "degenerate",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nuedexta\". This illustrates degenerate where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-005",
      "question": "What is baclofen used for in ALS management?",
      "expected_answer": "Baclofen is a GABA-B receptor agonist used to treat spasticity in ALS patients. Spasticity results from upper motor neuron degeneration and causes muscle stiffness, cramps, and involuntary spasms. Baclofen reduces spasticity by inhibiting spinal cord reflexes, improving patient comfort and mobility, though it does not slow disease progression.",
      "model_response": "\n\n\n\n\n\n, we have a role of the disease progression and disease.\n\n, we investigated the role of the role of the importance of the disease progression of the disease.\n\n\n\n\n\n, we have been identified a common genetic changes in the disease. We have a role in the most common genetic mutations in the disease.\n\n\n\n\n, we have a rare neurodegenerative diseases, we have been reported that the disease, we have a role in the disease progression of the disease.\n\n, we have also be associated with the disease, we have a rare neurodegenerative disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD.\n,\n,\n,\n,\n, we have a rare neurodegenerative disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"spasticity\". It also produced 2 potentially fabricated entities. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-006",
      "question": "What were the key findings of the original riluzole clinical trial by Bensimon et al.?",
      "expected_answer": "The Bensimon et al. 1994 trial was a double-blind, placebo-controlled study that demonstrated riluzole (100 mg/day) significantly improved survival in ALS patients at 12 months compared to placebo. The tracheostomy-free survival rate was higher in the riluzole group. The median survival benefit was approximately 2-3 months. The most common adverse effects were nausea, asthenia, and elevated liver enzymes.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n, we investigated that the study, we have a significant differences between the role in the importance of the disease progression. We found that the most common genetic changes in the disease. The most common mutations in the most common mechanisms of the disease.\n\n\n\n\n\n\n\nand the most common mutations in the most common genetic variants in the most common proteins, we have a common pathways, we identified in the ALS.\n\n\n\n\n\nand the most common mutations in the most common proteins, we investigated the molecular and RNA-binding protein (43) and RNA-associated TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"bensimon\". This illustrates plausible blending where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-008",
      "question": "What are common side effects of riluzole?",
      "expected_answer": "Common side effects of riluzole include nausea, asthenia (general weakness), elevated liver enzymes (hepatotoxicity requiring liver function monitoring), dizziness, and gastrointestinal disturbances. Regular monitoring of liver function tests is recommended, typically every month for the first three months and then periodically thereafter.",
      "model_response": "\n\n\n\n\n\n\n, we found that the most common in the disease progression of the disease.\n\n\n\n\n, we have a significant increase in the disease and the disease. We also reported that the disease-43, we found that the most common tau pathology in the tau pathology in AD patients with AD.\n\n\nand tau is a recent study, we investigated the role of tau pathology in the tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology.\n\n\nand tau is a common tau aggregation of tau aggregation of tau and tau pathology, we found that tau aggregation of tau pathology in the tau aggregation of tau aggregation of tau aggregation of tau pathology in AD, which are associated with tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology. The study, we have a role in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau and tau pathology in the tau aggregation of tau pathology in the tau aggregation of tau pathology in the tau pathology in AD, which is associated with tau pathology in the tau pathology in the tau pathology in the tau pathology.\n\n\n\n\n\nand tau pathology in the tau pathology in the tau plaques, we found that tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau and tau pathology in AD pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology, which is a role in the tau pathology.\n\nand tau pathology in the tau aggregation of tau pathology in AD and tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology, which is a role in the tau pathology in the tau pathology.\nand the aggregation of tau pathology, we found that tau pathology in AD and tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau pathology, which is a role in the",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nausea\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-009",
      "question": "What is AMX0035 and what was the outcome of the CENTAUR trial?",
      "expected_answer": "AMX0035 (brand name Relyvrio, later withdrawn from market) is a combination of sodium phenylbutyrate and taurursodiol (TURSO) that targets endoplasmic reticulum stress and mitochondrial dysfunction. The CENTAUR trial showed a modest slowing of functional decline on the ALSFRS-R scale compared to placebo over 24 weeks. However, the confirmatory Phase 3 PHOENIX trial failed to meet its primary endpoint, and the drug was voluntarily withdrawn from the market in 2024.",
      "model_response": "\n\n\nThe study, we conducted a comprehensive studies, we identified in the first study. The study, we used to identify the importance of the potential of ALS.\n\n\n\n\n\n\n\n\n\n\n, we have been reported that the role in the disease progression and disease progression of the disease.\nand the most common genetic mutations in the disease, we have a rare diseases, we have been identified in the disease. We have a significant differences between the most common genetic changes in the disease, we found that the disease, we have a more common variants in the disease.\n\n\n\n, we have a role of the most common genetic variants in the most common mutations in the most common genetic and FTD, we identified in AD pathology, we observed in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, tau pathology, and tau pathology. We found that tau pathology, we have a role of tau pathology, we investigated the aggregation, we show that tau pathology in AD pathology, we identified in AD, we observed in AD pathology, we have been reported that tau pathology in AD pathology in AD, and tau pathology in AD pathology, tau pathology in AD, and tau pathology.\n\nand tau pathology, we found that tau pathology, we investigated the aggregation of tau pathology in AD pathology in AD pathology in AD pathology, we identified a role in AD pathology, we have been reported that tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology, we observed in AD pathology.\n\nand the most common tau pathology in AD, we investigated the aggregation of tau pathology, we found that tau pathology, we have a role in AD pathology, we identified in AD pathology in AD pathology and tau pathology, we have been reported that tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology.\n\nand tau pathology, we have shown that tau pathology, we investigated the aggregation of tau pathology in AD pathology in AD pathology in AD pathology, we found that tau pathology, we identified a role in AD pathology, we have been reported that tau pathology in AD pathology, and tau pathology, tau pathology, tau pathology. We have been identified a role in AD pathology in AD pathology in AD pathology in AD, we investigated the aggregation of tau pathology in AD pathology, we have been shown that tau pathology in AD pathology in AD pathology, we found that tau pathology in AD pathology, tau pathology, and tau pathology in AD",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"sodium phenylbutyrate\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "DRUG-010",
      "question": "What is masitinib and what is its proposed mechanism in ALS?",
      "expected_answer": "Masitinib is not a real approved ALS treatment. While masitinib is a tyrosine kinase inhibitor that has been investigated in some clinical trials for various conditions, there is no confirmed drug called 'masitinib' with an established approval for ALS. This question tests whether the model fabricates clinical trial details about investigational compounds.",
      "model_response": "\n\n\nThe study, we have a recent study, we found that the first study, we identified a significant differences in the disease progression of AD pathology. The most common tau pathology in AD patients with AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau, and tau, and tau, tau, and tau, and tau, and tau, and tau, tau, and tau, tau, tau plaques, tau, and tau, tau, tau, and tau, tau, and tau, tau, and tau, tau pathology, tau, and tau, and tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau,",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"tyrosine kinase inhibitor\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about drug treatment."
    },
    {
      "question_id": "GENE-001",
      "question": "What is the most common genetic cause of familial ALS?",
      "expected_answer": "The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of familial ALS, accounting for approximately 40% of familial cases and about 5-10% of apparently sporadic cases in European populations. The mutation involves a GGGGCC repeat expansion in the first intron of the C9orf72 gene on chromosome 9p21.",
      "model_response": "\n\n\n\n\n, we have a rare disease. We found that the most common genetic and FTD.\n\n\n\nThe most common variant in the most common mutations in the most common protein in the tau pathology in the tau aggregation of tau pathology. The tau is also known to be associated with the tau pathology, which are the tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation, and tau pathology.\n\n\n\nand tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation of tau aggregation in the tau aggregation of tau aggregation, and tau aggregation, and tau aggregation of tau aggregation, and tau aggregation, which is a common tau pathology.\n\n\n\n\n, we have been identified by the aggregation of tau pathology in the tau aggregation of tau aggregation of tau pathology in AD, tau aggregation of tau pathology, tau aggregation of tau aggregation of tau pathology, and tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology, which are known to be associated with tau pathology.\n\nand tau pathology, we have been identified by the tau plaques, we investigated the aggregation of tau pathology in AD pathology in the aggregation of tau pathology in the tau pathology in the aggregation of tau pathology in the aggregation of tau pathology. We found that the tau pathology in the aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology and tau pathology, we investigated the tau pathology in the tau pathology in AD pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology.\n\n\n\nand the aggregation of tau pathology is a role in the aggregation of tau pathology in the aggregation of tau pathology in the aggregation of tau pathology, which is a common tau pathology and tau pathology. We have been identified in AD pathology, we investigated the tau pathology in the aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology and tau pathology.\n\n\nand the most common tau pathology, we have a role of tau aggregation of tau pathology, which is a common tau pathology in AD, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, tau pathology, and tau pathology.\nand the tau pathology is a recent study",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about gene mutation. It missed \"c9orf72\". It also produced 1 potentially fabricated entity. This illustrates confident fabrication where the model produced confidently wrong output about gene mutation."
    }
  ],
  "edge_cases": [
    {
      "question_id": "CARE-010",
      "question": "What is neurostimulation therapy for ALS and when is it recommended?",
      "expected_answer": "There is no established neurostimulation therapy that is recommended as standard of care for ALS. While various forms of neurostimulation (transcranial magnetic stimulation, transcranial direct current stimulation, spinal cord stimulation) have been explored in research settings, none have demonstrated sufficient efficacy in randomized controlled trials to be recommended for routine clinical use. This question tests whether the model fabricates treatment details about unproven interventions.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n\n, we investigated that the role of the potential in the importance of the development of the role in the role in the role in the role in the context of the treatment.\n\n\n\n\n\n\n\n\n\nThe study, we have a comprehensive research and clinical trials, we have been identified in the use of the current studies.\n\n\n\n\n\n\n\n, we have been developed the importance of the need for the development of the role in the context of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development of the development.\n\n\n\n\n\n, we have been identified a comprehensive research and clinical trials, we have been developed a comprehensive studies, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\nThe study, we have been conducted in the study, and the study, and clinical trials, and the use of the study, and clinical trials, and research, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials, and clinical trials.\n\n\n\n\n\nThe study, we have been developed a comprehensive research, and research.\n\n\n\n\n\n\n\n\n\n\n\nand the study, we have been identified in the study,\n\n\n,\nthe study,\n\n,\n,\n,\n,\nand the study,\n,\n,\nThe study,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "accuracy": 0.3333,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to adequately address 1 of 3 key facts about patient care. It matched \"research only\" but missed \"no established neurostimulation therapy for als\". This borderline response shows fragmented knowledge where the model captured some facts about patient care but missed critical details."
    },
    {
      "question_id": "DRUG-007",
      "question": "What is tofersen and for which ALS population is it indicated?",
      "expected_answer": "Tofersen (brand name Qalsody) is an antisense oligonucleotide (ASO) that targets SOD1 mRNA to reduce production of the toxic mutant SOD1 protein. It was approved by the FDA in 2023 under accelerated approval for ALS patients with SOD1 mutations, which account for approximately 2% of all ALS cases and about 12-20% of familial ALS cases. It is administered intrathecally.",
      "model_response": "\n\n\n\nThe study of the study, we have a significant differences in the disease progression. The study, we found that the most common genetic changes in the disease progression of the disease. We identified a role of the disease, we investigated the underlying the importance of the role in the role in the development of the disease progression and the disease progression of the disease.\n\n\n\n\n\nThe role of the role in the role in the role in the role in the role in the role in the role in the role in the role in the role of the pathogenesis of the importance of the underlying mechanisms, we have a role in the development of the disease. The most common mutations in the disease progression of the disease, we identified a rare diseases, we have been reported that the disease, we found that the disease, we have a common genetic and disease, we have a common genetic changes in the disease, we have a common mechanisms, and FTD.\n\n\n\n\nand the most common mutations in AD, we have a role of tau pathology, and tau aggregation, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau, and tau, and tau, and tau pathology in AD, and tau pathology, and tau pathology, tau pathology, tau, and tau, tau aggregation, and tau, and tau, and tau pathology, and tau, tau, tau, tau, tau, and tau, and tau, and tau pathology, tau, tau pathology, tau, tau, tau, and tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau pathology, tau, tau, tau, tau, tau, tau, tau, tau, and tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau, tau,",
      "accuracy": 0.25,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to adequately address 1 of 4 key facts about drug treatment. It matched \"sod1 mutations\" but missed \"antisense oligonucleotide\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-001",
      "question": "What drugs are FDA-approved for treating ALS?",
      "expected_answer": "Riluzole (approved 1995) and edaravone (approved 2017) are the two FDA-approved drugs for treating ALS. Riluzole is a glutamate antagonist that modestly extends survival by 2-3 months, and edaravone (brand name Radicava) is a free radical scavenger that may slow functional decline in a subset of patients.",
      "model_response": "\n\n\nThe study, we used a comprehensive research. The study, we identified a single-based approach to identify the potential of the future research.\n\n\n\n",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"riluzole\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-002",
      "question": "What is the mechanism of action of riluzole in ALS?",
      "expected_answer": "Riluzole is a benzothiazole that primarily acts as a glutamate release inhibitor. It reduces excitotoxicity by blocking presynaptic glutamate release, inhibiting voltage-gated sodium channels, and interfering with intracellular signaling events downstream of glutamate receptor activation. This reduces excitatory neurotransmission and may protect motor neurons from glutamate-mediated damage.",
      "model_response": "\n\n\n\n\n\n\n\n\n\nThe first study, we used a comprehensive data from the model. The study, we identified a single-based approach for the data.\n\n\n\n\n\n\n\n\n\n\n\n\nand the first study, we have a single-based sequencing and RNA-seq analysis of the RNA sequencing (43) and RNA sequencing. We performed the RNA sequencing.\n\n\n\n\n\nthe RNA sequencing\nThe RNA-binding protein-specific RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein, we used a single-type RNA-length RNA-seq. The RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (43) and RNA-binding protein-binding protein-binding protein-binding protein-binding protein, we identified a RNA-binding protein.\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5). The RNA-43-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein (Figure 5).\n\n\n\n\nand the RNA-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding protein-binding",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"glutamate release inhibitor\". It also produced 2 potentially fabricated entities. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-003",
      "question": "What is edaravone and how does it work in treating ALS?",
      "expected_answer": "Edaravone (brand name Radicava) is a free radical scavenger that was approved by the FDA in 2017 for ALS treatment. It acts by neutralizing reactive oxygen species (ROS) and reducing oxidative stress, which is implicated in motor neuron degeneration. In clinical trials, it slowed the decline in ALSFRS-R scores in a selected population of early-stage ALS patients.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n, we investigated the role of the impact on the potential for the importance of the development of the role in the disease progression.\n\n\n\n\n\n\n\n\nThe study, we have a role in the first study, we have been reported that the most common genetic mutations in the molecular mechanisms, and the accumulation in the aggregation, and the brain, and the brain, and the brain, and the brain, and the brain, and the brain. The brain, we found that the brain, we identified a role of the brain, we investigated the brain, we have been reported that the brain, we have a role in the brain, we have a role in the brain, we observed in the brain.\n\n\n\n\nand the molecular changes in the brain and the brain, we found that the brain, we identified a role of the brain, we investigated the brain, we have a role in the brain, we have a role in the brain, we have a role in the brain, we observed in the brain. We also present study, we have a role in the brain and the brain, we found that the brain, we identified a significant differences between the brain, we investigated the brain, we have a role in the brain, we have a role in the brain, we have a role in the brain, we observed that the brain.\n\n\n\n\n\n\n\n\nand the brain and the brain, we found that the brain, we identified a significant differences in the brain, we investigated the brain, we performed the brain, we used the brain, we examined the brain, we have a single-specific gene expression of the RNA sequencing (43) and RNA-binding protein. We found that the RNA-associated TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"free radical scavenger\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-004",
      "question": "What medication is used to treat pseudobulbar affect in ALS patients?",
      "expected_answer": "Nuedexta (dextromethorphan/quinidine) is the FDA-approved medication for pseudobulbar affect (PBA) in ALS patients. PBA causes involuntary, uncontrollable episodes of laughing or crying that are disproportionate to the patient's emotional state. Nuedexta combines dextromethorphan with quinidine sulfate to increase its bioavailability.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n\n\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,\n,",
      "accuracy": 0.0,
      "failure_mode": "degenerate",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nuedexta\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-005",
      "question": "What is baclofen used for in ALS management?",
      "expected_answer": "Baclofen is a GABA-B receptor agonist used to treat spasticity in ALS patients. Spasticity results from upper motor neuron degeneration and causes muscle stiffness, cramps, and involuntary spasms. Baclofen reduces spasticity by inhibiting spinal cord reflexes, improving patient comfort and mobility, though it does not slow disease progression.",
      "model_response": "\n\n\n\n\n\n, we have a role of the disease progression and disease.\n\n, we investigated the role of the role of the importance of the disease progression of the disease.\n\n\n\n\n\n, we have been identified a common genetic changes in the disease. We have a role in the most common genetic mutations in the disease.\n\n\n\n\n, we have a rare neurodegenerative diseases, we have been reported that the disease, we have a role in the disease progression of the disease.\n\n, we have also be associated with the disease, we have a rare neurodegenerative disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD.\n,\n,\n,\n,\n, we have a rare neurodegenerative disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and FTD, and AD, and Alzheimer's disease, and FTD, and FTD, and FTD, and",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"spasticity\". It also produced 2 potentially fabricated entities. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-006",
      "question": "What were the key findings of the original riluzole clinical trial by Bensimon et al.?",
      "expected_answer": "The Bensimon et al. 1994 trial was a double-blind, placebo-controlled study that demonstrated riluzole (100 mg/day) significantly improved survival in ALS patients at 12 months compared to placebo. The tracheostomy-free survival rate was higher in the riluzole group. The median survival benefit was approximately 2-3 months. The most common adverse effects were nausea, asthenia, and elevated liver enzymes.",
      "model_response": "\n\n\n\n\n\n\n\n\n\n\n, we investigated that the study, we have a significant differences between the role in the importance of the disease progression. We found that the most common genetic changes in the disease. The most common mutations in the most common mechanisms of the disease.\n\n\n\n\n\n\n\nand the most common mutations in the most common genetic variants in the most common proteins, we have a common pathways, we identified in the ALS.\n\n\n\n\n\nand the most common mutations in the most common proteins, we investigated the molecular and RNA-binding protein (43) and RNA-associated TDP-43, and TDP-43, and TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, and TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43, TDP-43",
      "accuracy": 0.0,
      "failure_mode": "plausible_blending",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"bensimon\". This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-008",
      "question": "What are common side effects of riluzole?",
      "expected_answer": "Common side effects of riluzole include nausea, asthenia (general weakness), elevated liver enzymes (hepatotoxicity requiring liver function monitoring), dizziness, and gastrointestinal disturbances. Regular monitoring of liver function tests is recommended, typically every month for the first three months and then periodically thereafter.",
      "model_response": "\n\n\n\n\n\n\n, we found that the most common in the disease progression of the disease.\n\n\n\n\n, we have a significant increase in the disease and the disease. We also reported that the disease-43, we found that the most common tau pathology in the tau pathology in AD patients with AD.\n\n\nand tau is a recent study, we investigated the role of tau pathology in the tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology.\n\n\nand tau is a common tau aggregation of tau aggregation of tau and tau pathology, we found that tau aggregation of tau pathology in the tau aggregation of tau aggregation of tau aggregation of tau pathology in AD, which are associated with tau aggregation of tau pathology in the tau pathology in the tau pathology in the tau pathology. The study, we have a role in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau and tau pathology in the tau aggregation of tau pathology in the tau aggregation of tau pathology in the tau pathology in AD, which is associated with tau pathology in the tau pathology in the tau pathology in the tau pathology.\n\n\n\n\n\nand tau pathology in the tau pathology in the tau plaques, we found that tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau and tau pathology in AD pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology, which is a role in the tau pathology.\n\nand tau pathology in the tau aggregation of tau pathology in AD and tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology, which is a role in the tau pathology in the tau pathology.\nand the aggregation of tau pathology, we found that tau pathology in AD and tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology of tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau pathology in the tau aggregation of tau pathology, which is a role in the",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"nausea\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    },
    {
      "question_id": "DRUG-009",
      "question": "What is AMX0035 and what was the outcome of the CENTAUR trial?",
      "expected_answer": "AMX0035 (brand name Relyvrio, later withdrawn from market) is a combination of sodium phenylbutyrate and taurursodiol (TURSO) that targets endoplasmic reticulum stress and mitochondrial dysfunction. The CENTAUR trial showed a modest slowing of functional decline on the ALSFRS-R scale compared to placebo over 24 weeks. However, the confirmatory Phase 3 PHOENIX trial failed to meet its primary endpoint, and the drug was voluntarily withdrawn from the market in 2024.",
      "model_response": "\n\n\nThe study, we conducted a comprehensive studies, we identified in the first study. The study, we used to identify the importance of the potential of ALS.\n\n\n\n\n\n\n\n\n\n\n, we have been reported that the role in the disease progression and disease progression of the disease.\nand the most common genetic mutations in the disease, we have a rare diseases, we have been identified in the disease. We have a significant differences between the most common genetic changes in the disease, we found that the disease, we have a more common variants in the disease.\n\n\n\n, we have a role of the most common genetic variants in the most common mutations in the most common genetic and FTD, we identified in AD pathology, we observed in AD, and tau pathology, and tau pathology, and tau pathology, and tau pathology, and tau pathology, tau pathology, and tau pathology. We found that tau pathology, we have a role of tau pathology, we investigated the aggregation, we show that tau pathology in AD pathology, we identified in AD, we observed in AD pathology, we have been reported that tau pathology in AD pathology in AD, and tau pathology in AD pathology, tau pathology in AD, and tau pathology.\n\nand tau pathology, we found that tau pathology, we investigated the aggregation of tau pathology in AD pathology in AD pathology in AD pathology, we identified a role in AD pathology, we have been reported that tau pathology in AD pathology in AD pathology in AD pathology in AD pathology in AD pathology, we observed in AD pathology.\n\nand the most common tau pathology in AD, we investigated the aggregation of tau pathology, we found that tau pathology, we have a role in AD pathology, we identified in AD pathology in AD pathology and tau pathology, we have been reported that tau pathology, tau pathology, tau pathology in AD, tau pathology, tau pathology.\n\nand tau pathology, we have shown that tau pathology, we investigated the aggregation of tau pathology in AD pathology in AD pathology in AD pathology, we found that tau pathology, we identified a role in AD pathology, we have been reported that tau pathology in AD pathology, and tau pathology, tau pathology, tau pathology. We have been identified a role in AD pathology in AD pathology in AD pathology in AD, we investigated the aggregation of tau pathology in AD pathology, we have been shown that tau pathology in AD pathology in AD pathology, we found that tau pathology in AD pathology, tau pathology, and tau pathology in AD",
      "accuracy": 0.0,
      "failure_mode": "confident_fabrication",
      "annotation": "The model failed to identify any of 0 of 4 key facts about drug treatment. It missed \"sodium phenylbutyrate\". It also produced 1 potentially fabricated entity. This borderline response shows fragmented knowledge where the model captured some facts about drug treatment but missed critical details."
    }
  ]
}